Market revenue in 2023 | USD 123.4 million |
Market revenue in 2030 | USD 576.5 million |
Growth rate | 24.6% (CAGR from 2023 to 2030) |
Largest segment | Autologous therapies |
Fastest growing segment | Autologous Therapies |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Allogeneic Therapies, Autologous Therapies |
Key market players worldwide | Novartis AG ADR, Gilead Sciences Inc, Bristol-Myers Squibb Co, Johnson & Johnson, JCR Pharmaceuticals Co Ltd, JW (Cayman) Therapeutics Co Ltd Ordinary Shares, Atara Biotherapeutics Inc, Medipost, Beiersdorf AG, Nkarta Inc Ordinary Shares |
Key Regions: U.S. , UK , Japan , Germany , Switzerland
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell therapy market will help companies and investors design strategic landscapes.
Autologous therapies was the largest segment with a revenue share of 97.49% in 2023. Horizon Databook has segmented the Canada cell therapy market based on allogeneic therapies, autologous therapies covering the revenue growth of each sub-segment from 2018 to 2030.
The cell therapy market in Canada is expected to exhibit significant growth over the forecast period due to the ongoing expansion of manufacturing facilities by key players in the market. For instance, in November 2021, Aspect Biosystems, a Canada-based biotechnology company, entered into an agreement with the University Health Network (UHN).
The primary objective of this partnership was to advance the development of bioprinted cell therapies targeting various genetic and acquired liver diseases. Such collaborations among major market players for developing cell therapies are expected to boost the competition in the country. Furthermore, researchers, government authorities, and scientists in the country are trying to develop therapies in Canada.
They are undertaking efforts to develop more affordable and accessible cell therapies. For instance, according to an article published by the government of Canada in February 2023, the National Research Council of Canada is developing new ways to create immunotherapies like CAR T-cell therapies for cancer patients.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada cell therapy market , including forecasts for subscribers. This country databook contains high-level insights into Canada cell therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account